8 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 5 with minor changes only.
Primary and study completion pushed from Jun 30, 2026 to Dec 30, 2026
Also in this update: Recruitment opened
Tianjin Medical University Cancer Institute and HospitalPhase 2 NCT07330063 Registry history of NCT07330063 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Tianjin Medical University Cancer Institute and HospitalNot applicable NCT07796906 Registry history of NCT07796906 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Tianjin Medical University Cancer Institute and HospitalPhase 2 NCT07372079 Registry history of NCT07372079 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Unknown → Recruiting
Also in this update: Study completion pushed from Jun 30, 2026 to Dec 30, 2026
Tianjin Medical University Cancer Institute and HospitalPhase 2 NCT06495515 Registry history of NCT06495515 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Aug 1, 2026 to Sep 18, 2026
Tianjin Medical University Cancer Institute and HospitalNot specified NCT07263620 Registry history of NCT07263620 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Tianjin Medical University Cancer Institute and HospitalPhase 1/2 NCT06093438 Registry history of NCT06093438 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Recruiting
Tianjin Medical University Cancer Institute and HospitalPhase 2 NCT06061146 Registry history of NCT06061146 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since May 2023); last known: Recruiting
Tianjin Medical University Cancer Institute and HospitalNot applicable NCT05890287 Registry history of NCT05890287 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-08 | NCT07866534 Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in… | Not Yet Recruiting | |
| 2026-10-02 | NCT07854977 Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line… | Phase 2 | Not Yet Recruiting |
| 2026-09-29 | NCT07845565 FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally… | Phase 2 | Not Yet Recruiting |
| 2026-09-29 | NCT07847671 Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC | Phase 2 | Not Yet Recruiting |
| 2026-09-24 | NCT07840092 Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular… | Recruiting | |
| 2026-09-21 | NCT07831889 Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | Not Yet Recruiting | |
| 2026-09-18 | NCT07828756 Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | Phase 2 | Not Yet Recruiting |
| 2026-09-17 | NCT07826806 Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 10 | |
| Phase 1/2 | 7 | |
| Phase 2 | 143 | |
| Phase 2/3 | 1 | |
| Phase 3 | 8 | |
| Phase 4 | 4 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent… | Uterine Cervical Neoplasms | Recruiting | 2026-08-25 |
| NCT05035147 | Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer | Pancreatic Cancer | Recruiting | 2021-09-21 |
| NCT07302841 | Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer Non-resectable | Not Yet Recruiting | 2025-12-24 |
| NCT07254416 | A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients | Breast Cancer Patients Treated With T-DXd | Not Yet Recruiting | 2025-11-28 |
| Phase 3 | ||||
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of… | HCC - Hepatocellular Carcinoma | Recruiting | 2026-08-05 |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in… | Pancreatic Cancer, Adult | Recruiting | 2026-07-10 |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following… | Pancreatic Cancer | Recruiting | 2026-06-08 |
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal… | Breast Cancer | Recruiting | 2026-01-20 |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally… | Esophageal Squamous Cell Carcinoma | Recruiting | 2022-06-01 |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After… | Esophageal Squamous Cell Carcinoma (ESCC) | Not Yet Recruiting | 2025-11-24 |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor… | Advanced and Metastatic NSCLC | Not Yet Recruiting | 2024-12-16 |
| NCT05678933 | AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH | Peripheral T-cell Lymphoma Targeted Therapy | Enrolling by Invitation | 2023-01-10 |
| Phase 2/3 | ||||
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | Pancreatic Cancer | Not Yet Recruiting | 2024-05-10 |
| Phase 2 | ||||
| NCT07162506 | dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction… | Esophageal Cancer | Recruiting | 2026-10-15 |
| NCT07318831 | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for… | Neuroblastoma (NB) | Recruiting | 2026-10-01 |
| NCT07372079 | Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach… | Breast Cancer | Recruiting | 2026-09-28 |
| NCT07330063 | Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in… | Gastrectomy | Recruiting | 2026-09-22 |
| NCT06495515 | Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast… | CANCER | Recruiting | 2026-09-17 |
| NCT07817082 | Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer | Advanced Breast Cancer With Ultra-Low HER2 Expression | Recruiting | 2026-09-14 |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of… | HCC - Hepatocellular Carcinoma | Recruiting | 2026-09-03 |
| NCT07321015 | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced… | Platinum-sensitive | Recruiting | 2026-08-21 |
| NCT06570447 | Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL | Diffuse Large B-Cell Lymphoma-Recurrent | Recruiting | 2026-08-03 |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting | 2026-07-29 |
| NCT07733830 | Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC | Esophageal Cancer | Recruiting | 2026-07-29 |
| NCT07726433 | Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV | Chemotherapy-Induced Nausea and Vomiting (CINV) | Recruiting | 2026-07-24 |
Lung Cancer (37) · Breast Cancer (30) · Non-Small Cell Lung Cancer (NSCLC) (29) · Liver Cancer (25) · Esophageal Cancer (17) · Pancreatic Cancer (17) · Cholangiocarcinoma (12) · Gastric Cancer (12) · Head & Neck Cancer (11) · Non-Hodgkin Lymphoma (10)